Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53.

Molecular cancer therapeutics - 1 May 2007

Graat Harm C A, Carette Jan E, Schagen Frederik H E, Vassilev Lyubomir T, Gerritsen Winald R, Kaspers Gertjan J L, Wuisman Paul I J M, van Beusechem Victor W

Abstract excerpt

Strategies to treat cancer by restoring p53 tumor suppressor functions are being actively investigated. These approaches range from expressing an exogenous p53 gene in p53 mutant cancers to antagonizing a p53 inhibitor in p53 wild-type (WT) cancer cells. In addition, exogenous p53 is used to stre...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Cell Count
Share to Genes, p53

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Reporter

Share to Imidazoles

Share to Oncolytic Viruses

Share to Piperazines

Share to Proto-Oncogene Proteins c-mdm2

Source

Identifiers

PMID: 17513604
DOI: 10.1158/1535-7163.MCT-06-0631

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17513604-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53.PMID 17513604Read ↗

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) AntagonistsSemantic proximity Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

Targeting the p53–MDM2 interaction to treat cancerSemantic proximity Read ↗

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in CancerSemantic proximity Read ↗

Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradationSemantic proximity Read ↗

Translational approaches targeting the p53 pathway for anti-cancer therapy.Semantic proximity Read ↗

Targeting the MDM2-p53 Interaction for Cancer TherapySemantic proximity Read ↗

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapySemantic proximity Read ↗

MDM2: current research status and prospects of tumor treatmentSemantic proximity Read ↗

MDM2 inhibitors in sarcomas: results and next stepsSemantic proximity Read ↗

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity Read ↗

Small-Molecule MDM2 Antagonists as a New Therapy Concept for NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.